‘There Were Mistakes, But I am Not an Insider Trader,’ Says Rajat Gupta, Former Head of McKinsey & Co (FirstPost)
Rajat Gupta, former head of McKinsey & Co has revealed the story of his fall from grace in his memoir Mind Without Fear to be published next week. In a slew of interviews to the media, Gupta has reiterated that he has not written the book to ‘defend’ himself or to ‘relitigate’ the case. The memoir, he says, tells his side of the story ‘in my own voice and what I went through and how I see the facts as I see them and I narrate them,” he said, to CNBC-TV18.
Insider Buys Of The Week: Air Transport, Fidelity National, Revlon (Benzinga)
Conventional wisdom says that insiders and 10 percent owners really only buy shares of a company for one reason — they believe the stock price will rise and they want to profit from it. So insider buying can be an encouraging signal for potential investors, particularly during periods of uncertainty. Here’s a look at a few notable insider purchases reported in the past week. Revlon: Revlon Inc REV 7.29% saw a director step up to the buy window last week. At $17.42 to $21.27 apiece, the 355,000 shares acquired via trust cost that director around $7.06 million. That brought his stake up to almost 45.6 million shares, which compares with less than 53 million shares listed as outstanding.
Monday 3/25 Insider Buying Report: ETRN, KW (Nasdaq.com)
Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned dollars to make a purchase, is that they expect to make money. Today we look at two noteworthy recent insider buys. At Equitrans Midstream, a filing with the SEC revealed that on Thursday, CEO Thomas F. Karam bought 250,000 shares of ETRN, at a cost of $20.47 each, for a total investment of $5.12M. Bargain hunters are able to pick up ETRN even cheaper than Karam did, with shares trading as low as $20.18 at last check today which is 1.4% below Karam’s purchase price. Equitrans Midstream Corp is trading off about 0.2% on the day Monday. This purchase marks the first one filed by Karam in the past year.
What Did This CEO Just Do with Personal Shares of Adamis Pharma (NASDAQ:ADMP)? (AnalystRatings)
Today, the President & CEO of Adamis Pharma (ADMP), Dennis Phd Carlo, sold shares of ADMP for $30.04K. In addition to Dennis Phd Carlo, 2 other ADMP executives reported Sell trades in the last month. Based on Adamis Pharma’s latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $4.15 million and GAAP net loss of $12.81 million. In comparison, last year the company earned revenue of $2.84 million and had a GAAP net loss of $8.03 million. Currently, Adamis Pharma has an average volume of 424.5K.
Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) Insider Trading Activity – Major Shareholder Sold 417,000 shares of Stock (MarketExclusive)
Insider Trading Activity For Crinetics Pharmaceuticals Inc (NASDAQ:CRNX): Vivo Capital Fund Viii, L.P. , Major Shareholder of Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) reportedly Sold 417,000 shares of the company’s stock at an average price of 22.25 for a total transaction amount of $9,278,250.00.